Effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccine in preventing hospitalization with laboratory confirmed influenza during the 2009-2010 and 2010-2011 seasons

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 4, 2013, Pages 865-873

  Domínguez, Angela ^a,b   Castilla, Jesús ^b,c   Godoy, Pere ^b,d   Delgado Rodríguez, Miguel ^b,e   Saez, Marc ^b,f   Soldevila, Núria ^b   Astray, Jenaro ^g   Mayoral, José María ^h   Martín, Vicente ^b,i   Quintana, José María ^b,j   González Candelas, Fernando ^b,k   Galán, Juan Carlos ^b,l   Tamames, Sonia ^m   Castro, Ady ⁿ   Baricot, Maretva ^b   Garín, Olatz ^b,o   Pumarola, Tomás ^p  

^a UNIVERSITY OF BARCELONA   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^d GENERALITAT DE CATALUNYA   (Spain)

^e UNIVERSITY OF JAÉN   (Spain)

^f UNIVERSITY OF GIRONA   (Spain)

^g Comunidad de Madrid ^*  (Spain)

^h Servicio de Vigilancia de Andalucia   (Spain)

ⁱ UNIVERSITY OF LEÓN   (Spain)

^j Hospital Galdakao Usansolo   (Spain)

^k UNIVERSITY OF VALENCIA   (Spain)

^l HOSPITAL RAMÓN Y CAJAL   (Spain)

^m Servicio de Programas de Salud y Prevención de la Dirección Técnica de Recursos Humanos y Gestión de Centros Gerencia de Servicios Sociales   (Spain)

ⁿ INSTITUTO DE SALUD CARLOS III   (Spain)

^o INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^p Red Española de Investigación en Patología Infecciosa REIPI   (Spain)

more..

Author keywords

Effectiveness; Hospitalization; Influenza vaccine; Laboratory confirmed influenza; Pneumococcal polysaccharide vaccine

Indexed keywords

INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE;

2009 H1N1 INFLUENZA; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HOSPITALIZATION; HUMAN; INFLUENZA A (H3N2); INFLUENZA B; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; PANDEMIC INFLUENZA; SEASONAL INFLUENZA; SPAIN; STREPTOCOCCUS PNEUMONIA; VACCINATION;

EFFECTIVENESS; HOSPITALIZATION; INFLUENZA VACCINE; LABORATORY-CONFIRMED INFLUENZA; PNEUMOCOCCAL POLYSACCHARIDE VACCINE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COSTS AND COST ANALYSIS; FEMALE; HOSPITALIZATION; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; SPAIN; YOUNG ADULT;

EID: 84877115048     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.23090     Document Type: Article

References (44)

1. Centers for Disease Control and Prevention (CDC). Swine influenza A (H1N1) infection in two chil-dren-Southern California, March-April 2009. MMWR Morb Mortal Wkly Rep 2009; 58:400-2; PMID:19390508.
2. Red Nacional de Vigilancia Epidemiológica. Vigilancia de la gripe en España. Temporada 2010-2011. Available at: http://vgripe.isciii.es/ gripe.AccessedonSeptember15, 2012.
3. WHO. Recommended viruses for influenza vaccines for use in the 2010-2011 northern hemisphere influenza season. Wkly Epidemiol Rec 2010; 85:81-92; PMID:20210260.
4. Walter ND, Taylor TH, Shay DK, Thompson WW, Brammer L, Dowell S F, et al.; Active Bacterial Core Surveillance Team. Influenza circulation and the burden of invasive pneumococcal pneumonia during a non-pandemic period in the United States. Clin Infect Dis 2010; 50:175-83; PMID:20014948; http://dx.doi.org/10.1086/649208.
5. McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev 2006; 19:571-82; PMID:16847087; http://dx.doi.org/10.1128/CMR.00058-05.
6. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 2008; 198:962-70; PMID:18710327; http://dx.doi.org/10.1086/591708.
7. Gupta RK, George R, Nguyen-Van-Tam JS. Bacterial pneumonia and pandemic influenza planning. Emerg Infect Dis 2008; 14:1187-92; PMID:18680640; http://dx.doi.org/10.3201/eid1408.070751.
8. Brundage J F. Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. Lancet Infect Dis 2006; 6:303-12; PMID:16631551; http://dx.doi.org/10.1016/S1473-3099(06)70466-2.
9. Maruyama T, Taguchi O, Niederman MS, Morser J, Kobayashi H, Kobayashi T, et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ 2010; 340:c1004; PMID:20211953; http://dx.doi.org/10.1136/bmj.c1004.
10. Vila-Córcoles A, Ochoa-Gondar O, Hospital I, Ansa X, Vilanova A, Rodríguez T, et al.; EVAN Study Group. Protective effects of the 23-valent pneumococ-cal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin Infect Dis 2006; 43:860-8; PMID:16941367; http://dx.doi.org/10.1086/507340.
11. Domínguez A, Izquierdo C, Salleras L, Ruiz L, Sousa D, Bayas JM, et al.; Working Group for the Study of Prevention of CAP in the Elderly. Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly. Eur Respir J 2010; 36:608-14; PMID:20075048; http://dx.doi.org/10.1183/09031936.00171309.
12. Jackson LA, Neuzil KM, Yu O, Benson P, Barlow WE, Adams AL, et al. Vaccine Safety Datalink. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003; 348:1747-55; PMID:12724480; http://dx.doi.org/10.1056/NEJMoa022678.
13. Skull SA, Andrews RM, Byrnes GB, Kelly HA, Nolan TM, Brown G V, et al. Prevention of community-acquired pneumonia among a cohort of hospitalized elderly: benefit due to influenza and pneumococcal vaccination not demonstrated. Vaccine 2007; 25:4631-40; PMID:17478015; http://dx.doi.org/10.1016/j.vac-cine. 2007.03.015.
14. Nichol KL. The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung disease. Vaccine 1999; 17(Suppl 1):S91-3; PMID:10471189; http://dx.doi.org/10. 1016/S0264-410X(99)00114-0.
15. Hung IFN, Leung AYM, Chu DWS, Leung D, Cheung T, Chan CK, et al. Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a prospective cohort study. Clin Infect Dis 2010; 51:1007-16; PMID:20887208; http://dx.doi.org/10.1086/656587.
16. Christenson B, Hedlund J, Lundbergh P, Ortqvist A. Additive preventive effect of influenza and pneumo-coccal vaccines in elderly persons. Eur Respir J 2004; 23:363-8; PMID:15065822; http://dx.doi.org/10.1183/09031936.04.00063504.
17. Gilchrist SA, Nanni A, Levine O. Benefits and effectiveness of administering pneumococcal polysaccharide vaccine with seasonal influenza vaccine: an approach for policymakers. Am J Public Health 2012; 102:596-605; PMID:22397339; http://dx.doi.org/10.2105/AJPH.2011.300512.
18. Viasus D, Paño-Pardo JR, Pachón J, Riera M, López-Medrano F, Payeras A, et al. Novel Influenza A(H1N1) Study Group of the Spanish Network for Research in Infectious Diseases (REIPI). Pneumonia complicating pandemic (H1N1) 2009: risk factors, clinical features, and outcomes. Medicine (Baltimore) 2011; 90:328-36; PMID:21862936.
19. Shieh WJ, Blau DM, Denison AM, Deleon-Carnes M, Adem P, Bhatnagar J, et al. 2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States. Am J Pathol 2010; 177:166-75; PMID:20508031; http://dx.doi.org/10.2353/ajpath.2010.100115.
20. Koon K, Sanders CM, Green J, Malone L, White H, Zayas D, et al. Co-detection of pandemic (H1N1) 2009 virus and other respiratory pathogens. Emerg Infect Dis 2010; 16:1976-8; PMID:21122236; http://dx.doi.org/10.3201/ eid1612.091697.
21. Palacios G, Hornig M, Cisterna D, Savji N, Bussetti AV, Kapoor V, et al. Streptococcus pneumoniae coinfection is correlated with the severity of H1N1 pandemic influenza. PLoS ONE 2009; 4:e8540; PMID:20046873; http://dx.doi.org/10. 1371/journal.pone.0008540.
22. Riquelme R, Riquelme M, Rioseco ML, Inzunza C, Gomez Y, Contreras C, et al. Characteristics of hospitalised patients with 2009 H1N1 influenza in Chile. Eur Respir J 2010; 36:864-9; PMID:20185421; http://dx.doi.org/10.1183/09031936. 00180409.
23. De Serres G, Lampron N, La Forge J, Rouleau I, Bourbeau J, Weiss K, et al. Importance of viral and bacterial infections in chronic obstructive pulmonary disease exacerbations. J Clin Virol 2009; 46:129-33; PMID:19665425; http://dx.doi.org/10.1016/j.jcv.2009.07.010.
24. Nichol KL, Baken L, Wuorenma J, Nelson A. The health and economic benefits associated with pneu-mococcal vaccination of elderly persons with chronic lung disease. Arch Intern Med 1999; 159:2437-42; PMID:10665892; http://dx.doi.org/10.1001/archinte.159.20.2437.
25. Grabenstein JD. Effectiveness and serotype coverage: key criteria for pneumococcal vaccines for adults. Clin Infect Dis 2012; 55:255-8; PMID:22495543; http://dx.doi.org/10.1093/cid/cis354.
26. Musher DM. Editorial commentary: should 13-valent protein-conjugate pneumococcal vaccine be used routinely in adults? Clin Infect Dis 2012; 55:265-7; PMID:22495544; http://dx.doi.org/10.1093/cid/cis364.
27. Fedson DS, Nicolas-Spony L, Klemets P, van der Linden M, Marques A, Salleras L, et al. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe. Expert Rev Vaccines 2011; 10:1143-67; PMID:21810065; http://dx.doi.org/10.1586/erv.11.99.
28. Al-Sukhni W, Avarino P, McArthur MA, McGeer A. Impact of public vaccination programs on adult vaccination rates: two examples from Ontario, Canada. Vaccine 2008; 26:1432-7; PMID:18272261; http://dx.doi.org/10.1016/j. vaccine.2008.01.001.
29. Andrews RM. Assessment of vaccine coverage following the introduction of a publicly funded pneumococcal vaccine program for the elderly in Victoria, Australia. Vaccine 2005; 23:2756-61; PMID:15780723; http://dx.doi.org/10.1016/j. vaccine.2004.11.039.
30. Begun F, Pebody R. Annual pneumococcal polysac-charide vaccine uptake in 65 years old and over for England. Influenza immunization uptake monitoring programme. London: Department of Health and Health Protection Agency, 2008.
31. Jackson LA, Baxter R, Naleway AL, Belongia EA, Baggs J. Patterns of pneumococcal vaccination and revaccination in elderly and non-elderly adults: a Vaccine Safety Datalink study. BMC Infect Dis 2009; 9:37; PMID:19321001; http://dx.doi.org/10.1186/1471-2334-9-37.
32. Santibáñez TA, Zimmerman RK, Nowalk M P, Jewell IK, Bardella IJ. Physician attitudes and beliefs associated with patient pneumococcal polysaccharide vaccination status. Ann Fam Med 2004; 2:41-8; PMID:15053282; http://dx.doi.org/10.1370/afm.53.
33. Johnson DR, Nichol KL, Lipczynski K. Barriers to adult immunization. Am J Med 2008; 121(Suppl 2):S28-35; PMID:18589065; http://dx.doi.org/10.1016/j. amjmed.2008.05.005.
34. Nichol KL. Pneumococcal vaccination and revaccination in the elderly population. J Infect Dis 2010; 201:659-61; PMID:20113178; http://dx.doi.org/10. 1086/651376.
35. Butler JC, Breiman R F, Campbell J F, Lipman HB, Broome CV, Facklam RR. Pneumococcal poly-saccharide vaccine efficacy. An evaluation of current recommendations. JAMA 1993; 270:1826-31; PMID:8411526; http://dx.doi.org/10. 1001/jama.1993.03510150060030.
36. Musher DM, Manof SB, Liss C, McFetridge RD, Marchese RD, Bushnell B, et al. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis 2010; 201:516-24; PMID:20092407; http://dx.doi.org/10.1086/649839.
37. Domínguez A, Alonso J, Astray J, Baricot M, Cantón R, Castilla J, et al. Grupo de Trabajo del Proyecto CIBERESP de Casos y Controles sobre la Gripe Pandémica. Risk factors of influenza (H1N1) 2009 hospitalization and effectiveness of pharmaceutical and nonpharmaceutical interventions in its prevention: a case-control study. Rev Esp Salud Publica 2011; 85:3-15; PMID:21750838.
38. European Commission. Commission decision of 30 April 2009 amending Decision 2002/253/EC laying down case definitions for reporting communicable diseases to the Community network under Decision No 2119/98/EC of the European Parliament and of the Council. Available at: http://eurlex.europa.eu/LexUriServ/ LexUriServ.do?uri=OJ:L:2009:110:0058:0059:EN:PDF.AccessedonSeptember15, 2012.
39. World Health Organization. WHO(2009b) CDC Protocol of realtime RTPCR for influenza A (H1N1). October 2009. Available at: http://www.who.int/csr/ resources/pub-lications/swineflu/CDCRealtimeRTPCR-SwineH1Assay-2009-20090430. pdf.AccessedonSeptember16, 2012.
40. Puig-Barberà J, Arnedo-Pena A, Pardo-Serrano F, Tirado-Balaguer MD, Pérez-Vilar S, Silvestre-Silvestre E, et al. Surveillance and Vaccine Evaluation Group during the autumn 2009 H1N1 pandemic wave in Castellón, Spain. Effectiveness of seasonal 2008-2009, 2009-2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellón, Spain. A testnegative, hospital-based, case-control study. Vaccine 2010; 28:7460-7; PMID:20875486; http://dx.doi.org/10.1016/j. vaccine.2010.09.042.
41. Song JY, Cheong HJ, Heo JY, Noh JY, Choi WS, Park DW, et al. Effectiveness of the pandemic influenza A/H1N1 2009 monovalent vaccine in Korea. Vaccine 2011; 29:1395-8; PMID:21199701; http://dx.doi.org/10.1016/j.vaccine. 2010.12.050.
42. Simpson CR, Ritchie LD, Robertson C, Sheikh A, McMenamin J. Vaccine effectiveness in pandemic influenza-primary care reporting (VIPER): an observational study to assess the effectiveness of the pandemic influenza A (H1N1)v vaccine. Health Technol Assess 2010; 14:313-46; PMID:20630126.
43. Katz MH. Interpreting the results. In: Katz MH. Multivariable analysis. A practical guide for clinicians. Third edition. Cambridge: Cambridge University Press, 2011:140-161.
44. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70:41-55; http://dx.doi.org/10.1093/biomet/70.1.41.